Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
- PMID: 28414749
- PMCID: PMC5393888
- DOI: 10.1371/journal.pone.0175792
Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
Erratum in
-
Correction: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.PLoS One. 2017 Jun 28;12(6):e0180623. doi: 10.1371/journal.pone.0180623. eCollection 2017. PLoS One. 2017. PMID: 28658276 Free PMC article.
Abstract
Background: The fusion (F) protein of RSV is the major vaccine target. This protein undergoes a conformational change from pre-fusion to post-fusion. Both conformations share antigenic sites II and IV. Pre-fusion F has unique antigenic sites p27, ø, α2α3β3β4, and MPE8; whereas, post-fusion F has unique antigenic site I. Our objective was to determine the antigenic variability for RSV/A and RSV/B isolates from contemporary and historical genotypes compared to a historical RSV/A strain.
Methods: The F sequences of isolates from GenBank, Houston, and Chile (N = 1,090) were used for this analysis. Sequences were compared pair-wise to a reference sequence, a historical RSV/A Long strain. Variability (calculated as %) was defined as changes at each amino acid (aa) position when compared to the reference sequence. Only aa at antigenic sites with variability ≥5% were reported.
Results: A total of 1,090 sequences (822 RSV/A and 268 RSV/B) were analyzed. When compared to the reference F, those domains with the greatest number of non-synonymous changes included the signal peptide, p27, heptad repeat domain 2, antigenic site ø, and the transmembrane domain. RSV/A subgroup had 7 aa changes in the antigenic sites: site I (N = 1), II (N = 1), p27 (N = 4), α2α3β3β4(AM14) (N = 1), ranging in frequency from 7-91%. In comparison, RSV/B had 19 aa changes in antigenic sites: I (N = 3), II (N = 1), p27 (N = 9), ø (N = 4), α2α3β3β4(AM14) (N = 1), and MPE8 (N = 1), ranging in frequency from 79-100%.
Discussion: Although antigenic sites of RSV F are generally well conserved, differences are observed when comparing the two subgroups to the reference RSV/A Long strain. Further, these discrepancies are accented in the antigenic sites in pre-fusion F of RSV/B isolates, often occurring with a frequency of 100%. This could be of importance if a monovalent F protein from the historical GA1 genotype of RSV/A is used for vaccine development.
Conflict of interest statement
Figures



Similar articles
-
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12. Vaccine. 2019. PMID: 31416644
-
Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.J Virol. 2016 Oct 14;90(21):10022-10038. doi: 10.1128/JVI.01196-16. Print 2016 Nov 1. J Virol. 2016. PMID: 27581977 Free PMC article.
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30. Vaccine. 2018. PMID: 30389195
-
Clinical Potential of Prefusion RSV F-specific Antibodies.Trends Microbiol. 2018 Mar;26(3):209-219. doi: 10.1016/j.tim.2017.09.009. Epub 2017 Oct 17. Trends Microbiol. 2018. PMID: 29054341 Review.
-
[Research Progress in the F Gene and Protein of the Respiratory Syncytial Virus].Bing Du Xue Bao. 2015 Mar;31(2):201-6. Bing Du Xue Bao. 2015. PMID: 26164949 Review. Chinese.
Cited by
-
Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.Viruses. 2020 Jan 15;12(1):102. doi: 10.3390/v12010102. Viruses. 2020. PMID: 31952261 Free PMC article. Review.
-
Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.Vaccines (Basel). 2020 Apr 21;8(2):192. doi: 10.3390/vaccines8020192. Vaccines (Basel). 2020. PMID: 32326278 Free PMC article.
-
Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-like Illness in Sicily (Italy) from 2017 to 2023.Viruses. 2024 May 26;16(6):851. doi: 10.3390/v16060851. Viruses. 2024. PMID: 38932144 Free PMC article.
-
RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.J Virol. 2025 Jul 22;99(7):e0053125. doi: 10.1128/jvi.00531-25. Epub 2025 Jul 3. J Virol. 2025. PMID: 40607811 Free PMC article.
-
Structures of respiratory syncytial virus G bound to broadly reactive antibodies provide insights into vaccine design.Sci Rep. 2025 Mar 13;15(1):8666. doi: 10.1038/s41598-025-92886-w. Sci Rep. 2025. PMID: 40082629 Free PMC article.
References
-
- Peret TC, Hall CB, Hammond GW, Piedra PA, Storch GA, Sullender WM, et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000;181: 1891–6. doi: 10.1086/315508 - DOI - PubMed
-
- Anderson LJ, Bingham P, Hierholzer JC. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol. 1988;62: 4232–8. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=253856&tool=pm... - PMC - PubMed
-
- Tan L, Coenjaerts FEJ, Houspie L, Viveen MC, van Bleek GM, Wiertz EJHJ, et al. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol. American Society for Microbiology (ASM); 2013;87: 8213–26. doi: 10.1128/JVI.03278-12 - DOI - PMC - PubMed
-
- PATH. RSV Vaccine Snapshot [Internet]. 2016 [cited 10 Jan 2017]. Available: http://www.path.org/vaccineresources/details.php?i=1562
-
- Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A. 1987;84: 5625–9. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=298915&tool=pm... - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources